CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 178 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02576951
NCT02576951Phase 1Completed
CompareCT.gov

Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 in Healthy Subjects Following a Subcutaneous Administration of a Lyophilized Formulation or a Solution Formulation

Eli Lilly and Company·interventional·Posted Oct 15, 2015·Updated Feb 26, 2019

In Brief

A Phase 1 clinical trial evaluating Galcanezumab and Placebo for Healthy. Completed, enrolled 178 participants across 1 site.

Detailed Summary

The purposes of this study are: * To evaluate tolerability of the Galcanezumab solution injectable formulation (Part A) * To measure how much of the Galcanezumab lyophilized (freeze dried) injectable formulation is absorbed into the blood stream and how long it takes the body to get rid of it compared to the Galcanezumab solution injectable formulation after a single injection under the skin (subcutaneous \[SC\]) (Part B). Information about any side effects that may occur will also be collected. Each part of the study will last about six months. Participants may only enroll in one part.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 15, 2015
Enrollment StartOct 19, 2015
Primary CompletionSep 3, 2016
Study CompletionJan 8, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.7 years ago

Interventions

Galcanezumabdrug

Administered SC

Placebodrug

Administered SC